staceywhite, Author at European Medical Journal - Page 16 of 195

Gene Therapy: Living With(out) Haemophilia?

Since research on human gene therapy began, the expectations regarding its potential in treating haemophilia have been high. Haemophilia…

Ranking Treatments for Lenalidomide-Refractory Multiple Myeloma post DRd

Multiple myeloma is the second most common haematological malignancy, with an increasing global incidence…

Re-evaluating European Haemophilia Standards

TEST In this feature, the authors critically analyse the European standards for Haemophilia Treatment Centres (HTC), examining their…

The Immunotherapy Landscape for Multiple Myeloma

Take a look at our latest haematology infographic, which explores the current immunotherapy treatment landscape for multiple myeloma…

Rituximab in Adults with Autoimmune Haematological Disorders

Rituximab, a monoclonal anti-CD20 antibody, has proven to be an excellent therapeutic agent for haematological diseases. Low-dose…

100 Years of von Willebrand Disease

von Willebrand disease (VWD) is considered the most common inherited bleeding disorder, even surpassing haemophilia A. Nevertheless, VWD…

Synchronous Twin Malignancies in a Young Female: A Case Report

Synchronous twin malignancies, defined as the simultaneous occurrence of two distinct primary cancers in the same patient, represent a…

Vitamin K-Dependent Bleeding Linked to Topiramate

Topiramate is a well-known medication used for migraine and epilepsy. Bleeding is a rare and less documented side-effect of this treatment…

Review of the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

THIS SUMMER, the welcoming city of Glasgow, UK, proudly hosted the EAACI Congress 2025, a pivotal event that brought together…

Bridging HAE Treatment Gaps

Hereditary angioedema (HAE) attacks are unpredictable and can be debilitating and potentially life-threatening. The burden of HAE disease…